AI Is Revolutionizing Biopharma Innovation, Collaboration

In a world where technological innovation constantly redefines the limits of what’s possible, generative artificial intelligence (GenAI) has become a key catalyst for business transformation. It learns from user interactions across various fields, from chatbots in e-commerce and election campaigns to personalized recommendations on entertainment platforms, to enhance the user experience.

GenAI can generate completely new and original solutions from existing data. Its potential to produce text, images, audio, and video has captured our imagination since the launch of ChatGPT, the first software capable of holding real-time conversations enabling more intuitive, predictive, and efficient interactions between humans and machines.

Its impact has been so significant that Stanford University ranks it as the most transformative technology of the 21st century, comparing its disruptive presence to that of the internet and mobile phones. The market is projected to exceed US$1 trillion by 2034, with a CAGR of 44,2%, driven by the media and entertainment, transportation, financial services, and healthcare sectors. Moreover, thanks to platforms such as business intelligence, machine learning, and robotics, efficient and automated solutions are being developed across various industries worldwide (DemandSage, 2025).

Due to their computing capacity and access to vast amounts of data, AI models generate significant savings in time and resources, but they also present challenges: high energy consumption, the risk of job displacement, data privacy concerns, difficulties in distinguishing real from fake content, potential copyright infringements, and the tendency to attribute human-like capabilities that they do not actually possess. Even so, countries like Mexico could become benchmarks for innovation and competitiveness. There are 362 AI companies in the country generating more than 11,000 jobs, reflecting the sustained growth of the ecosystem in recent years (Endeavor, 2025).

In the healthcare sector, AI analyzes large volumes of clinical and population data to identify epidemiological risks and enable early interventions in chronic diseases and pandemics (Nature, 2025). In the pharmaceutical industry, it has been pivotal both in translational medicine, accelerating the discovery of new molecules that improve patients’ quality of life, and in reinventing companies.

At the biopharmaceutical company I lead, we believe that scientific and technological innovation only makes sense when it translates into real benefits for patients. Today, artificial intelligence represents a key tool in our business reconfiguration process, a deep transformation aimed at strengthening the efficiency of our operations and accelerating scientific discovery, without altering the foundations that define us as a company committed to ethics, integrity, and the well-being of people.

Like upgrading a home's wiring, this reconfiguration process is about optimizing the way we work while keeping our core structure intact. In organizations like ours, AI helps us "update" our operating systems (scientific, clinical, and business) to respond with agility to changes in the environment, preserve the quality of research, and deliver effective treatments to those who need them most. Below, I share five keys in which this tool is revolutionizing our sector:

1. Find new therapeutic targets. GenAI allows us to decipher complex biological systems by analyzing millions of data from diverse patients. Advanced algorithms process tissue images, profile molecular characteristics and, using deep learning, help study cancer cells to identify new biomarkers and therapeutic targets, such as protein degraders, beyond what is already validated by science.

2. Discovering Promising Molecules. Developing a drug can take 10 to 13 years and exceed US$3 billion, with only 1 in every 10,000 compounds reaching the market (Farmaindustria, 2025). Faced with this challenge, AI has become our ally. In highly automated laboratories, scientists and robots collaborate to analyze billions of data points on the human genome, chemical compounds, and protein structures to discover promising combinations and validate therapeutic targets.

Each result is recorded and fed back into the system, improving the design of future molecules. Thus, we combine AI with ethics and responsible clinical research to transform science into real solutions, accelerating access to personalized therapies. Additionally, we compare these findings with information from clinical trials and pharmacoeconomic data, automating their analysis and facilitating the preparation of value dossiers that support our scientific evidence before regulatory authorities.

3. Transform clinical research. AI is revolutionizing clinical research by optimizing patient recruitment, selecting the most suitable hospitals, automating data analysis, and creating predictive models that complement traditional statistical methods. It also strengthens pharmacovigilance, increasing accuracy and reducing human error, while promoting the use of real-world data to analyze the efficacy, safety, and feasibility of our drugs outside the controlled trial environment, thereby strengthening clinical and regulatory decision-making (International Journal of Surgery, 2023).

4. Enhancing patient care. The pandemic accelerated the shift toward digital channels, and today AI allows us to improve communication with healthcare professionals, provide personalized scientific content, and support continuing medical education. We have also implemented AI tools that analyze medical records and help physicians identify at-risk patients, facilitating timely diagnoses and appropriate treatments. In Latin America, initiatives such as Patient Care Route – Gastric Cancer Audit with AI and the Skin Guard app, focused on early melanoma detection, are already making a tangible difference in patient care.

5. Learning, growing, and collaborating. In an increasingly competitive environment, AI drives productivity and work quality, with studies reporting increases of up to 25% in speed and 40% in efficiency (Harvard Business School, 2023). We have integrated GenAI and ChatGPT across multiple operations, creating secure internal tools that summarize complex information, plan projects, extract insights from large volumes of data, and automate repetitive tasks. This accelerates decision-making and frees up time for strategic innovation, always under strict standards of ethics, privacy, and cybersecurity.

In human resources, we use MyGrowth, an AI-based platform that personalizes career plans, connects employees with projects and courses, and helps managers assign tasks according to strengths and interests. In this way, we foster professional development and a culture of continuous learning, aligned with business needs and, ultimately, with our purpose: transforming patients’ lives through science.

Ultimately, GenAI is transforming not only healthcare but all productive sectors, optimizing processes, inventory management, traceability, decision-making, and experiences. However, with great opportunities come great responsibilities. Ethical use, data protection, and workforce adaptation are challenges we must address collectively. In this context, are we ready to lead this transformation in a responsible and sustainable way?